BenchSci, a Toronto, Canada-based provider of a machine learning platform to identify and resolve preclinical research inefficiencies in drug discovery, raised $22m in Series B financing.

The round was led by F-Prime Capital, with participation from Northleaf Capital Partners and existing investors Gradient Ventures, Inovia Capital, Golden Ventures, and Real Ventures.

The company’s first product, AI-Assisted Antibody Selection, focused only on antibodies.

Now, BenchSci has launched its new AI-Assisted Reagent Selection product, which expands to other important reagents, including recombinant proteins, RNAi, CRISPR, cell lines, and more.

As one of the earliest pharmaceutical companies to benefit from AI-Assisted Antibody Selection, Novartis will also be the first BenchSci customer to deploy the new AI-Assisted Reagent Selection product. | To read full story, visit https://startuparound.com/read/1580855409.54255/BenchSci-Raises-$22M-in-Series-B-Funding?ref=audio_experience